Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Seres Therapeutics (MCRB) Change in Receivables (2019 - 2025)

Seres Therapeutics' Change in Receivables history spans 5 years, with the latest figure at -$8.7 million for Q4 2024.

  • For Q4 2024, Change in Receivables fell 6.0% year-over-year to -$8.7 million; the TTM value through Sep 2025 reached -$8.7 million, down 6.0%, while the annual FY2024 figure was -$8.7 million, 200.0% down from the prior year.
  • Change in Receivables for Q4 2024 was -$8.7 million at Seres Therapeutics, up from -$9.9 million in the prior quarter.
  • Across five years, Change in Receivables topped out at $11.2 million in Q2 2024 and bottomed at -$9.9 million in Q3 2024.
  • The 4-year median for Change in Receivables is $237000.0 (2020), against an average of $506800.0.
  • The largest annual shift saw Change in Receivables surged 8714.71% in 2020 before it plummeted 2962.03% in 2021.
  • A 4-year view of Change in Receivables shows it stood at $6.0 million in 2020, then soared by 35.75% to $8.1 million in 2021, then crashed by 200.57% to -$8.2 million in 2023, then fell by 6.0% to -$8.7 million in 2024.
  • Per Business Quant, the three most recent readings for MCRB's Change in Receivables are -$8.7 million (Q4 2024), -$9.9 million (Q3 2024), and $11.2 million (Q2 2024).